Carregant...
PATH-21. ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
BACKGROUND: Bevacizumab in combination with chemotherapy has shown activity in recurrent glioblastoma patients, with responding patients having improved survival as well as quality of life. Recently, we found that low gene expression of angiotensinogen (AGT) was predictive for bevacizumab response i...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216569/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.677 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|